Resources for patients living with Vitiligo.
In September, the FDA approved topical ruxolitinib cream (Opzelura, Incyte) as the first JAK inhibitor to treat AD. Del Rosso noted its list of indications could expand in the near future. Recently released Phase 3 clinical trial program data shows positive outcomes for this JAK inhibitor in treating vitiligo and AA.
Incyte offers financial assistance and savings programs for eligible patients prescribed Opzelura. If you have specific questions on these program, you may call IncyteCARES for Opzelura at 1-800-583-6964. Or click link below.
Our goal is 10,000 participants in the study and GlobalSkin Members can play an important role by encouraging patient participation. Don’t miss out on having your patient community be represented in the in the GRIDD data!